Benjamin Hughes, Senior Vice President of Artificial Intelligence and Real World Data at IQVIA, has again collated the leading AI and RWD-focused articles published this month across the journals. Here, we take a look at the pharma-published entries, some on COVID-19.
Various pharma – combine with FWD, NIH and EMA, to publish their FAIR principles and the need for Common Data Elements (CDEs) in their implementation
FAIR data sharing: The roles of common data elements and harmonization
Pfizer – looks at the role of RWE in oncology approvals during the period 2016-19
Pfizer/Sanofi – highlight the importance of machine learning in health economics and outcomes research, to identify clinically relevant sub-groups
Janssen/OHDSI – also with IQVIA authors, they published a systematic review of first line anti-hypertensives using RWD from five million patients across five countries
Roche – speculate that COVID-19 will accelerate the use of RWE in access and evidence/data-based decision-making
Life after COVID-19: R WE going to help?
Janssen – using Columbia observational medical outcomes partnership (OMOP) data and four trial comparisons, suggest that trial eligibility criteria are so different to real-world populations that they cannot be used alone for label/licensing
AstraZeneca – levers the fusion database linked to SHA claims to profile healthcare utilisation of 20,000 patients on LAMA/LABA fixed dose combinations
AstraZeneca – uses the IQVIA PMX+ database to profile treatment patterns for younger patients with chronic lymphocytic leukaemia
Merck – uses the German IGef claims database to profile 500 patients with multiple sclerosis, high HDA especially within the young RRMS population
GSK – lever IQVIA UK IMRD (EMR) to suggest higher persistence and adherence to ICS/LABA in asthma across 5,000 patients
GSK – on ICS/LABA/LAMA combination in Japan, levering the JMDC claims database to profile overall utilisation patterns
Boehringer Ingelheim – sponsor a study using Japanese MDV claims to profile bleeding incident rates of NOAC patients undergoing surgery
Pfizer – lever Optum EMR to determine stroke rates from patients undergoing elective lumbar fusion
Roche/Genentech – lever McKesson U.S. oncology network to examine patient outcomes with HER2+ breast cancer, with the pathological response (pCR) after nPT and adjuvant trastuzumab (aT)
Source article: Benjamin Hughes on LinkedIn